Targeting Hyaluronic Acid and Peritoneal Dissemination in Colorectal Cancer.

Abstract

Peritoneal metastasis (PM) from colorectal cancer (CRC) carries a significant mortality rate for patients and treatment is challenging. The development of PM is a multistep process involving detachment, adhesion, invasion and colonization of the peritoneal cavity. Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) for PM from CRC has some benefit but overall survival is poor and recurrence rates are high. Treatments to prevent the development of peritoneal metastasis could have the potential to improve CRC survival and disease-free outcomes. The ability of cancer cells to invade the peritoneum and become established as metastatic tumors is influenced by a multifactorial process. Hyaluronic acid (HA) has been shown to coat the mesothelial cells of the peritoneum and has been demonstrated to be utilized in various malignancies as part of the metastatic process in peritoneal dissemination. CD44, RHAMM (CD168) and ICAM-1 have all been shown to be binding partners for HA. Targeting HA-mediated binding may prevent adhesion to distant sites within the peritoneum through suppression of interaction of these molecules. Here we review the current literature and discuss key molecules involved with PM dissemination, with the potential to target these mechanisms in the delivery of future treatments.

• Authors: Faris Soliman, Lin Ye, Wenguo Jiang, Rachel Hargest
• Journal: Clinical colorectal cancer (Clin Colorectal Cancer) Vol. 21 Issue 2 Pg. e126-e134 (06 2022) ISSN: 1938-0674 [Electronic] United States
• PMID: 34955378 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Hyaluronic Acid

Topics

• Colorectal Neoplasms (pathology)
• Combined Modality Therapy
• Humans
• Hyaluronic Acid (therapeutic use)
• Hyperthermia, Induced
• Peritoneal Neoplasms (secondary, therapy)
• Peritoneum (pathology)